AFP and hepatocellular carcinoma: Furthermore, in surveillance of early HCC from CLD, Egfl7 had a much better AUROC (0.787–0.800 vs. 0.563–0.675), sensitivity (75.2–75.9% vs. 36.1–61.8%) and accuracy (73.5–74.1% vs. 59.7–61.9%) than AFP, indicating Egfl7 as a better serum marker than AFP in the surveillance of early HCC from CLD.